Merit Medical Systems Inc., a leader in healthcare technology, has announced the acquisition of Biolife Delaware, L.L.C., a company based in Sarasota, Florida, known for its patented hemostatic devices under the brand names StatSeal and WoundSeal. The transaction, valued at approximately $120 million, sees Biolife becoming a wholly-owned subsidiary of Merit. This strategic acquisition is expected to enhance Merit's product portfolio by providing clinicians with advanced hemostasis solutions to improve post-procedure care. The acquisition is projected to add around $18 million in annual revenue by fiscal year 2026, with a strong growth trajectory. The financial guidance for the full year 2025 has been updated to reflect the impact of this acquisition.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.